1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Insulin Resistance - Pipeline Review, H1 2017

Insulin Resistance - Pipeline Review, H1 2017

  • March 2017
  • -
  • Global Markets Direct
  • -
  • 45 pages

Insulin Resistance - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance - Pipeline Review, H1 2017, provides an overview of the Insulin Resistance (Metabolic Disorders) pipeline landscape.

Insulin resistance (IR) is a condition in which the body's cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time causing the body’s own sensitivity to the hormone to be reduced. Symptoms include lethargy, hunger, difficulty concentrating and high blood pressure. Predisposing factors include obesity and hypertension.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Insulin Resistance - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Insulin Resistance (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insulin Resistance (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.

Insulin Resistance (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Insulin Resistance (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Insulin Resistance (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Insulin Resistance (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Insulin Resistance (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Insulin Resistance (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Insulin Resistance (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Insulin Resistance (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Insulin Resistance - Pipeline Review, H1 2017
Introduction
Global Markets Direct Report Coverage
Insulin Resistance - Overview
Insulin Resistance - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Insulin Resistance - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Insulin Resistance - Companies Involved in Therapeutics Development
Amgen Inc
AusBio Ltd
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Hadasit Medical Research Services and Development Ltd
Pfizer Inc
Prometheon Pharma LLC
Sanofi
Insulin Resistance - Drug Profiles
ATA-842 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
englerin A - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
FC-98 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
L-2286 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
MD-960 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
MD-961 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Peptide to Agonize Oxytocin Receptor for Obesity and Insulin Resistance - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
RG-7992 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
SAR-088 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecule to Target AGTR1 and PPAR Gamma for Hypertension and Insulin Resistance - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules to Inhibit TRIP-Br2 for Obesity and Insulin Resistance - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
SYM-401 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
TM-25659 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Insulin Resistance - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Insulin Resistance, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Insulin Resistance - Pipeline by Amgen Inc, H1 2017
Insulin Resistance - Pipeline by AusBio Ltd, H1 2017
Insulin Resistance - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Insulin Resistance - Pipeline by GlaxoSmithKline Plc, H1 2017
Insulin Resistance - Pipeline by Hadasit Medical Research Services and Development Ltd, H1 2017
Insulin Resistance - Pipeline by Pfizer Inc, H1 2017
Insulin Resistance - Pipeline by Prometheon Pharma LLC, H1 2017
Insulin Resistance - Pipeline by Sanofi, H1 2017
Insulin Resistance - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Insulin Resistance, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Pipeline Review, H2 2016

Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 o ...

Hyperinsulinemia - Pipeline Review, H2 2016

Hyperinsulinemia - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Hyperinsulinemia - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia – Pipeline Review, H2 2016, provides an overview ...

Hypoglycemia - Pipeline Review, H1 2017

Hypoglycemia - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • February 2017
  • by Global Markets Direct

Hypoglycemia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia – Pipeline Review, H1 2017, provides an overview of the ...

Autism - Pipeline Review, H1 2017

February 2017 $ 2000

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.